Publicações

Sophia Primary Analysis: A Phase 3 (P3) Study of Margetuximab (M) plus Chemotherapy (C) Versus Trastuzumab (T) plus C in Patients (Pts) with Her2+Metastatic (Met) Breast Cancer (Mbc) After Prior Anti-Her2 Therapies (Tx).

AuthID
P-00R-4AD

Author(s)

Rugo, HS

Im, SA

Wright, GLS

Escriva de Romani, S

DeLaurentiis, M

Cortes, J

Bahadur, SW

Haley, BB

Oyola, RH

Riseberg, DA

Musolino, A

Cardoso, F

Curigliano, G

Kaufman, PA

Pegram, MD

Edlich, S

Hong, S

Rock, EP

Gradishar, WJ

Tipo de Documento

Abstract

Year published

2019

Publicado

in JOURNAL OF CLINICAL ONCOLOGY, ISSN: 0732-183X

Volume: 37, Número: 15

Conference

Annual Meeting of the American-Society-Of-Clinical-Oncology (Asco), Date: MAY 31-JUN 04, 2019, Location: Chicago, IL, Patrocinadores: Amer Soc Clin Oncol

Indexing

Wos^®

Google Scholar^®

Metadata
Fontes

Publication Identifiers

DOI: 10.1200/jco.2019.37.15_suppl.1000

Wos: WOS:000487345803587

Source Identifiers

ISSN: 0732-183X

Export Publication Metadata

Lista Marked

Adicionar à lista Marked

Info

At this moment we don't have any links to full text documens.

Sophia Primary Analysis: A Phase 3 (P3) Study of Margetuximab (M) plus Chemotherapy (C) Versus Trastuzumab (T) plus C in Patients (Pts) with Her2+Metastatic (Met) Breast Cancer (Mbc) After Prior Anti-Her2 Therapies (Tx).

Links Úteis

Ajuda

Autenticação Federada (Clique na imagem)

Sophia Primary Analysis: A Phase 3 (P3) Study of Margetuximab (M) plus Chemotherapy (C) Versus Trastuzumab (T) plus C in Patients (Pts) with Her2+Metastatic (Met) Breast Cancer (Mbc) After Prior Anti-Her2 Therapies (Tx).

Links Úteis

Ajuda